Acurx Pharmaceuticals, Inc. Q3 FY2025 earnings call

• On August 4, effected a 1-for-20 reverse stock split, regaining NASDAQ compliance on August 26.
• In September, Australian Patent Office granted a new patent for DNA polymerase 3C inhibitors. Acurx has multiple patents in various countries for ACX-375C program.
• In September, stockholders approved increasing authorized common stock shares from 200 million to 250 million.
• In October, received gross proceeds from exercise of 170,000 Series F warrants for ~$1.4 million. Selected to present at ID Week on new antimicrobials. Published results in Nature Communications on ibezapolstat bound to target. Recognize November as C. diff Awareness Month and support Peggy Lillis Foundation. Ibezapolstat has FDA QIDP and FAST TRACK designations and SME status in EU.

No product segments are detailed in the transcript; overall financials are provided. Cash ended the quarter at $5.9 million compared to $3.7 million as of December 31, 2024. Research and development expenses for the three months ended September 30, 2025, were $0.4 million, down from $1.2 million in the prior year. General and administrative expenses for the three months ended September 30, 2025, were $1.6 million, consistent with the prior year. Net loss for the three months ended September 30, 2025, was $2 million, or $1.23 per diluted share, compared to a net loss of $2.8 million, or $3.45 per diluted share in the prior year.

• Expect major news on next earnings call regarding potential partnerships. - Costs are expected to gradually decrease as the company continues to tighten its belt. - Has ~$5.9 million in cash plus $1.4 million after quarter end, and ~$9 million remaining on the equity line of credit, allowing it to bide time while waiting for partnerships or M&A activity.

• Forward-looking statements are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those in forward-looking statements. Investors should consider risks described in SEC filings.

Q: Given recent changes under the current FDA administration, do you see increased potential for the agency to prioritize domestically manufactured novel antibiotics?

A: See buds on the trees related to possible legislation, but not sure yet. PASTOR Act not a focus currently.

Q: Does the proposed clinical priority review voucher framework impact the company's regulatory approach or commercial strategy?

A: Would avail ourselves of the program at appropriate time, same strategy.

Q: Has the team explored the possibility of filing for approval based solely on the phase two ibezapolstat data?

A: Couldn't, need a safety database and phase three trial data.

Q: How might recent publications and presentations inform or potentially change your clinical strategy going forward?

A: Data is compelling, microbiome-sparing class effect makes confident, but doesn't change primary strategy.

Q: Any framework or timing around potential partnership discussions?

A: Partnership is two-way street, surprised if no major news on next earnings call.

Q: On QIDP and FAST TRACK designation, are there time limits or movement that has to go forward?

A: Once you get them, you have them in perpetuity.

Q: Are these OpEx numbers the numbers we should anticipate going forward?

A: Yes, costs will continue to gradually go down as the company tightens its belt.